Percentage of mice with detectable antidonor alloantibody3-150
| Agent Added to Pulse . | N . | Transfusion Week . | |||
|---|---|---|---|---|---|
| Pre . | 2 . | 4 . | 6 . | ||
| None | 38 | 03-151 | 45 — | 70 — | 100 — |
| IFN-γ (100 U/mL) | 10 | 0 | 80 (P < .05)3-152 | 100 (P < .05) | 100 (n/s) |
| AMG (1 mM) | 19 | 0 | 10 (P < .01) | 30 (P < .05) | 50 (P < .0005) |
| Colchicine (1 μg/mL) | 15 | 0 | 15 (P < .05) | 20 (P < .01) | 20 (P < .0001) |
| NH4Cl (50 mM) | 10 | 0 | 40 (n/s) | 80 (n/s) | 100 (n/s) |
| Chloroquine (0.1 mM) | 31 | 0 | 70 (P < .05) | 100 (P < .01) | 100 (n/s) |
| Brefeldin A (1 μg/mL) | 9 | 0 | 100 (P < .05) | 100 (n/s) | 100 (n/s) |
| MG115 (5 μM) | 9 | 0 | 100 (P < .05) | 100 (n/s) | 100 (n/s) |
| Agent Added to Pulse . | N . | Transfusion Week . | |||
|---|---|---|---|---|---|
| Pre . | 2 . | 4 . | 6 . | ||
| None | 38 | 03-151 | 45 — | 70 — | 100 — |
| IFN-γ (100 U/mL) | 10 | 0 | 80 (P < .05)3-152 | 100 (P < .05) | 100 (n/s) |
| AMG (1 mM) | 19 | 0 | 10 (P < .01) | 30 (P < .05) | 50 (P < .0005) |
| Colchicine (1 μg/mL) | 15 | 0 | 15 (P < .05) | 20 (P < .01) | 20 (P < .0001) |
| NH4Cl (50 mM) | 10 | 0 | 40 (n/s) | 80 (n/s) | 100 (n/s) |
| Chloroquine (0.1 mM) | 31 | 0 | 70 (P < .05) | 100 (P < .01) | 100 (n/s) |
| Brefeldin A (1 μg/mL) | 9 | 0 | 100 (P < .05) | 100 (n/s) | 100 (n/s) |
| MG115 (5 μM) | 9 | 0 | 100 (P < .05) | 100 (n/s) | 100 (n/s) |
APC were pulsed with donor platelets at a ratio of 10 platelets: 1 APC in the presence of the agents indicated, washed twice and 106 APC were transfused weekly.
Data are expressed as the percentage of recipients with detectable antidonor antibody by flow cytometry (rounded to nearest 5%).
The χ2 test of independent proportions was used to compare the agent-treated pulsed APC groups against the nontreated pulsed APC group (n/s indicates not significant).